Ordena

Cercar

12/04/2024 Assessing Outcomes of Patients Subject to Intensive Care to Facilitate Organ Donation: A Spanish Multicenter Prospective Study
Perez-Blanco, A, Acevedo, M, Padilla, M, Gomez, A, Zapata, L, Barber, M, Martinez, A, Calleja, V, Rivero, MC, Fernandez, E, Velasco, J, Flores, EM, Quindos, B, Rodriguez, ST, Virgos, B, Nebra, AC, Robles, JC, Moya, J, Trenado, J, Garcia, N, Vallejo, A, Herrero, E, Garcia, A, Rodriguez, ML, Garcia, F, Lara, R, Lage, L, Gil, FJ, Guerrero, FJ, Meilan, A, Del Prado, N, Fernandez, C, Coll, E, Dominguez-Gil, B. Assessing Outcomes of Patients Subject to Intensive Care to Facilitate Organ Donation: A Spanish Multicenter Prospective Study. TRANSPLANT INTERNATIONAL. 2024; 37DOI:10.3389/ti.2024.12791. PMID:38681973. IF:3.000(Q1/1D).
12/04/2024 An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study
Dunn, W, Li, YM, Singal, AK, Simonetto, DA, Diaz, LA, Idalsoaga, F, Ayares, G, Arnold, J, Ayala-Valverde, M, Perez, D, Gomez, J, Escarate, R, Fuentes-Lopez, E, Ramirez-Cadiz, C, Morales-Arraez, D, Zhang, W, Qian, SV, Ahn, JC, Buryska, S, Mehta, H, Dunn, N, Waleed, M, Stefanescu, H, Bumbu, A, Horhat, A, Attar, B, Agrawal, R, Cabezas, J, Echavaria, V, Cuyas, B, Poca, M, Soriano, G, Sarin, SK, Maiwall, R, Jalal, PK, Higuera-de-la-Tijera, F, Kulkarni, AV, Rao, PN, Guerra-Salazar, P, Skladany, L, Kubanek, N, Prado, V, Clemente-Sanchez, A, Rincon, D, Haider, T, Chacko, KR, Romero, GA, Pollarsky, FD, Restrepo, JC, Toro, LG, Yaquich, P, Mendizabal, M, Garrido, ML, Marciano, S, Dirchwolf, M, Vargas, V, Jimenez, C, Hudson, D, Garcia-Tsao, G, Ortiz, G, Abraldes, JG, Kamath, PS, Arrese, M, Shah, VH, Bataller, R, Arab, JP. An artificial intelligence-generated model predicts 90-day survival in alcohol-associated hepatitis: A global cohort study. HEPATOLOGY. 2024; 80(5)DOI:10.1097/HEP.0000000000000883. PMID:38607809. IF:15.800(Q1/1D).
11/04/2024 Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic Review
Uijterwijk, BA, Lemmers, DH, Fusai, GK, Zerbi, A, Salvia, R, Sparrelid, E, White, S, Björnsson, B, Mavroeidis, VK, Roberts, KJ, Mazzola, M, Cabus, SS, Soonawalla, Z, Korkolis, D, Serradilla, M, Pessaux, P, Luyer, M, Mowbray, N, Ielpo, B, Mazzotta, A, Kleeff, J, Boggi, U, Munoz, MAS, Goh, BKP, Andreotti, E, Wilmink, H, Ghidini, M, Zaniboni, A, Verbeke, C, Adsay, V, Bianchi, D, Besselink, MG, Abu Hilal, M, Nappo, G, Ghorbani, P, Malleo, G, Lancelotti, F, Napoli, N, Robinson, S, Khalil, K, Val, ARD, Mortimer, MCM, Al-Sarireh, B, Koh, YX, Bhogal, R, Serrablo, A, Gayet, B, Johansen, K, Ramaekers, M, Giani, A. Differences in Lymph Node Metastases Patterns Among Non-pancreatic Periampullary Cancers and Histologic Subtypes: An International Multicenter Retrospective Cohort Study and Systematic Review. ANNALS OF SURGICAL ONCOLOGY. 2024; 31(7)DOI:10.1245/s10434-024-15213-z. PMID:38602578. IF:3.500(Q1/2D).
11/04/2024 Cohort Profile: Barcelona Life Study Cohort (BiSC)
Dadvand, P, Gascon, M, Bustamante, M, Rivas, I, Foraster, M, Basagana, X, Cosin, M, Eixarch, E, Ferrer, M, Gratacos, E, Herrera, LG, Jimenez-Arenas, P, Júlvez, J, Morillas, A, Nieuwenhuijsen, MJ, Persavento, C, Pujol, J, Querol, X, García, OS, Vrijheid, M, Llurba, E, Gomez-Roig, MD, Sunyer, J. Cohort Profile: Barcelona Life Study Cohort (BiSC). INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2024; 53(3)DOI:10.1093/ije/dyae063. PMID:38725298. IF:5.900(Q1/1D).
11/04/2024 Spatial Bayesian distributed lag non-linear models (SB-DLNM) for small-area exposure-lag-response epidemiological modelling
Quijal-Zamorano, M, Martinez-Beneito, MA, Ballester, J, Mari-Dell'Olmo, M. Spatial Bayesian distributed lag non-linear models (SB-DLNM) for small-area exposure-lag-response epidemiological modelling. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY. 2024; 53(3)DOI:10.1093/ije/dyae061. PMID:38641428. IF:5.900(Q1/1D).
10/04/2024 Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study
Motzer, RJ, Porta, C, Eto, M, Powles, T, Gruenwald, V, Hutson, TE, Alekseev, B, Rha, SY, Merchan, J, Goh, JC, Lalani, AKA, De Giorgi, U, Melichar, B, Hong, SH, Gurney, H, Mendez-Vidal, MJ, Kopyltsov, E, Tjulandin, S, Gordoa, TA, Kozlov, V, Alyasova, A, Winquist, E, Maroto, P, Kim, M, Peer, A, Procopio, G, Takagi, T, Wong, SR, Bedke, J, Schmidinger, M, Rodriguez-Lopez, K, Burgents, J, He, CX, Okpara, CE, Mckenzie, J, Choueiri, TK. Lenvatinib Plus Pembrolizumab Versus Sunitinib in First-Line Treatment of Advanced Renal Cell Carcinoma: Final Prespecified Overall Survival Analysis of CLEAR, a Phase III Study. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(11)DOI:10.1200/JCO.23.01569. PMID:38227898. IF:41.900(Q1/1D).